Want to see IVVD full AI Analyst Report?
Top Page
Invivyd
(NASDAQ:IVVD)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.81
▼(-13.94% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by deep unprofitability and ongoing cash burn despite strong gross margins and improving revenue. Technicals are neutral but still reflect a weak longer-term trend, while valuation signals remain constrained by losses and no dividend. Earnings-call execution progress and upcoming pivotal milestones provide upside catalysts, but corporate/regulatory overhangs (Nasdaq bid deficiency and EUA transition) add risk.
Positive Factors
High-margin revenue growth
Improving revenue paired with exceptionally high gross margins indicates attractive product economics and the potential to retain substantial value from future sales. If growth continues, these economics could support reinvestment in development and commercialization while improving operating leverage over the next several quarters.
Negative Factors
Persistent cash burn and losses
Large ongoing losses and negative operating cash flow mean Invivyd is not yet funding its operations internally. Continued trial spending and commercialization investment could require additional external financing, limiting capital flexibility unless revenue growth and profitability improve materially.
Read all positive and negative factors
Positive Factors
Negative Factors
High-margin revenue growth
Improving revenue paired with exceptionally high gross margins indicates attractive product economics and the potential to retain substantial value from future sales. If growth continues, these economics could support reinvestment in development and commercialization while improving operating leverage over the next several quarters.
Read all positive factors
Invivyd (IVVD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$243.47M
Dividend YieldN/A
Average Volume (3M)3.87M
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth26.30%
EPS Growth59.47%
CountryUS
Employees122
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding294,758,760
10 Day Avg. Volume4,143,995
30 Day Avg. Volume3,869,146
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.76
Price to Sales (P/S)7.96
P/FCF Ratio-7.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside963.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.53
Revenue Forecast (FY)$60.15M
Invivyd Business Overview & Revenue Model
Company Description
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company'...
How the Company Makes Money
Invivyd’s business model is to generate revenue from commercializing its monoclonal antibody products and, where applicable, from strategic arrangements that can include collaborations, licensing, or other partnering structures; however, specific ...
Invivyd Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call presents strong commercial momentum (PEMGARDA +22% YoY), advancing pivotal trial progress with encouraging safety signals (IDMC reduced monitoring), confirmed neutralization versus a recent Omicron subvariant, an expanding discovery pipeline, and a robust cash position after an April ATM raise. Near-term challenges include elevated clinical spend and burn during the pivotal, continued uncertainty around regulatory outcomes and efficacy readouts driven by event rates, declining COVID vaccine revenue, and imperfect external surveillance and media traction. On balance, concrete operational and scientific progress and expected high efficacy positioning outweigh the near-term financial and market uncertainties.Positive Updates
PEMGARDA Revenue Growth
PEMGARDA grew 22% year-over-year in 1Q2026 versus 1Q2025; leading indicators show continued growth and the company is scaling direct-to-consumer and AI channels to further increase disease and brand awareness.
Negative Updates
Declining COVID Vaccine Utilization and Revenue
Management noted declining COVID vaccine utilization and associated revenue, though no specific revenue decline percentage was provided.
Read all updates
Q1-2026 Updates
Positive
Negative
PEMGARDA Revenue Growth
PEMGARDA grew 22% year-over-year in 1Q2026 versus 1Q2025; leading indicators show continued growth and the company is scaling direct-to-consumer and AI channels to further increase disease and brand awareness.
Read all positive updates
Company Guidance
In the Q1 2026 call management guided that the pivotal DECLARATION study (upsized in early April) has resumed full‑speed recruitment and is expected to finish imminently, the IDMC recommended shortening post‑dose monitoring from 2 hours to 30 minutes, and the LIBERTY study will open and begin recruiting shortly; commercially, PEMGARDA grew 22% year‑over‑year versus 1Q 2025, Q1 included substantial clinical spend to support DECLARATION but the company said cash remains strong after an April at‑the‑market raise; scientifically, they confirmed neutralization versus Omicron BA.3.2, noted vaccine efficacy peaks at roughly 50% for a limited time while vaccines produce systemic reactogenicity in ~80–90% of people with ~3–3.5 symptom days, argued a monoclonal with even 10–15% efficacy can provide net symptomatic benefit, and said VYD2311 dosing was chosen to deliver titers consistent with an expected ~70–90% protection against symptomatic disease.Invivyd Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
66
Positive
Cash Flow
31
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.37M | 53.43M | 25.38M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 53.32M | 49.68M | 23.77M | 0.00 | 0.00 | 0.00 |
| EBITDA | -107.31M | -50.38M | -166.81M | -205.75M | -225.80M | -219.41M |
| Net Income | -107.33M | -52.49M | -169.93M | -198.64M | -241.32M | -226.79M |
Balance Sheet | ||||||
| Total Assets | 218.88M | 276.88M | 129.51M | 229.18M | 383.17M | 620.09M |
| Cash, Cash Equivalents and Short-Term Investments | 160.08M | 226.69M | 69.35M | 200.64M | 371.99M | 591.42M |
| Total Debt | 8.39M | 2.49M | 1.30M | 2.17M | 3.72M | 0.00 |
| Total Liabilities | 37.80M | 35.34M | 61.98M | 51.71M | 27.20M | 62.07M |
| Stockholders Equity | 181.08M | 241.54M | 67.54M | 177.47M | 355.97M | 558.02M |
Cash Flow | ||||||
| Free Cash Flow | -109.66M | -58.29M | -170.63M | -173.78M | -221.69M | -184.82M |
| Operating Cash Flow | -108.42M | -58.13M | -170.49M | -173.16M | -219.99M | -184.74M |
| Investing Cash Flow | -1.24M | -155.00K | -140.00K | 280.68M | -230.67M | -50.71M |
| Financing Cash Flow | 234.83M | 215.63M | 39.33M | 1.04M | 506.00K | 662.68M |
Invivyd Technical Analysis
Negative
0.94
Price Trends
0.77
Positive
1.00
Negative
1.49
Negative
Market Momentum
0.03
Positive
50.05
Neutral
26.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVVD, the sentiment is Negative. The current price of 0.94 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.77, and below the 200-day MA of 1.49, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 26.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVVD.
Invivyd Risk Analysis
Invivyd disclosed 87 risk factors in its most recent earnings report. Invivyd reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Invivyd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $397.87M | -1.92 | -137.39% | ― | ― | -27.00% | |
56 Neutral | $827.01M | -5.50 | -41.33% | ― | 278712.12% | 26.59% | |
53 Neutral | $423.73M | -24.13 | -5.76% | ― | ― | 93.45% | |
52 Neutral | $947.49M | -12.83 | -34.03% | ― | ― | -5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $243.47M | -2.09 | -59.73% | ― | 26.30% | 59.47% |
* Healthcare Sector Average
IVVD
Invivyd
0.83
-0.33
-28.79%
LRMR
Larimar Therapeutics
3.83
-0.10
-2.54%
RCKT
Rocket Pharmaceuticals
3.86
0.60
18.40%
FDMT
4D Molecular Therapeutics
14.97
8.00
114.78%
DSGN
Design Therapeutics
15.14
9.32
160.14%
Invivyd Corporate Events
Business Operations and StrategyExecutive/Board Changes
Invivyd appoints Marc Elia CEO amid board reshuffle
Positive
Sep 1, 2026
On August 30, 2026, Invivyd appointed board chairman and healthcare investor Marc Elia as chief executive officer, formalizing the move with a compensation package that includes a $750,000 salary, large option grant, and robust severance and chang...
Delistings and Listing ChangesRegulatory Filings and Compliance
Invivyd Receives Nasdaq Notice for Bid Price Deficiency
Negative
Jul 24, 2026
On July 23, 2026, Invivyd, Inc. disclosed that it received a deficiency letter from Nasdaq after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, placing the company out of compliance with Nasdaq’s ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Invivyd Plans Post-EUA Pathway for PEMGARDA Antibody
Negative
Jul 6, 2026
On July 6, 2026, Invivyd announced that it had received formal notice from the U.S. Food and Drug Administration that the Emergency Use Authorization for its COVID-19 monoclonal antibody PEMGARDA will terminate on June 29, 2027, following the U.S....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.